skip to Main Content

Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease

Patent extends patent coverage for eltoprazine to 2034 New York, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative…

Read More
Back To Top
×Close search
Search